Retrospective study of the safety and efficacy of hydroxychloroquine among patients with immune Thrombopenia (ITP).
Hydroxychloroquine (HCQ) is usually used in Patients with Systemic Lupus Erythematosus (SLE) in order to treat mainly arthralgia or skin manifestations of this disease. A few studies have previously shown that HCQ could also be useful for treating autoimmune cytopenia and particularly autoimmune thrombopenia associated with SLE. In this retrospective study, the investigators have selected patients followed in our center and who have received HCQ either for an authentic SLE or because they had positive antinuclear antibodies (\> 1/160e on HEP2 cells) without a definite SLE according to the American College of Rheumatology. The main goal of this study is to compare the efficacy of HCQ in these two subgroups of patients.
Study Type
OBSERVATIONAL
Enrollment
40
Number of patients achieving a response (Platelet count > 30x10^9/L and doubling of the baseline count) or a complete response (platelet count > 100x10^9/L for a t least 6 months)
Time to achieve a response, concomittant(s) treatment(s), need for an emergency treatment
Time frame: one year
Tolerance of Hydroxychloroquine
allergy, myopathy HCQ induced
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.